Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

Neurocrine Bio. (NBIX) PT Lowered to $179 at BofA Securities

February 7, 2025 6:08 AM EST

BofA Securities analyst Tazeen Ahmad lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $179.00 (from $184.00) while maintaining a Buy rating.

The analyst comments "NBIX announced FY24 Ingrezza revenues of $2.31bn (+26% y/y, ours: $2.316bn, cons: $2.32bn). On FY25 outlook, the company guided to FY25 sales of... More